SITAVIG
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SITAVIG (SITAVIG).
Sitavig (acyclovir) is a synthetic nucleoside analogue that inhibits viral DNA replication. It is phosphorylated to acyclovir triphosphate, which competitively inhibits viral DNA polymerase and incorporation into viral DNA, leading to chain termination.
| Metabolism | Acyclovir is metabolized to a small extent by aldehyde oxidase and alcohol dehydrogenase. The major metabolite is 9-carboxymethoxymethylguanine (CMMG). It is primarily excreted renally via glomerular filtration and tubular secretion. |
| Excretion | Primarily renal; approximately 80% of the dose is excreted unchanged in urine within 24 hours. Minor fecal excretion (less than 10%). |
| Half-life | Terminal elimination half-life is approximately 20 hours in adults with normal renal function. In patients with renal impairment (CrCl <30 mL/min), half-life increases to up to 40 hours, necessitating dose adjustment. |
| Protein binding | Approximately 15% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution is about 0.7 ± 0.2 L/kg, indicating distribution into total body water and some tissue binding. |
| Bioavailability | Bioavailability of the buccal tablet is approximately 70% relative to oral acyclovir, with sustained absorption across the buccal mucosa. |
| Onset of Action | Mucoadhesive buccal tablet: Clinical antiviral effect (reduction of viral shedding and lesion healing) begins within 30 minutes to 1 hour after application, with maximum plasma concentrations achieved at 1.5 to 2 hours. |
| Duration of Action | Duration of antiviral effect is approximately 12 hours, supporting twice-daily dosing. Lesion healing and symptom resolution typically occur within 4 to 6 days; therapy should be continued for 7 days. |
| Molecular Weight | 344.84 |
Topical: Apply one 50 mg buccal tablet to the upper gum above the incisor region once daily for 14 days.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required for hepatic impairment. |
| Pediatric use | Safety and effectiveness in pediatric patients below 16 years have not been established. |
| Geriatric use | No specific dose adjustment recommended; monitor for adverse effects due to potential age-related decline in organ function. |
| 1st trimester | Category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks. Clotrimazole troche should only be used during the first trimester if clearly needed. |
| 2nd trimester | Category C: Same as first trimester; use only if clearly needed. |
| 3rd trimester | Category C: Same as first and second trimesters; use only if clearly needed. |
Clinical note
Comprehensive clinical and safety monograph for SITAVIG (SITAVIG).
| Placental transfer | Limited data; clotrimazole is poorly absorbed systemically after oral administration (<3% bioavailability), so placental transfer is expected to be minimal. However, no specific studies on placental transfer have been performed. |
| Breastfeeding | It is not known whether clotrimazole is excreted in human milk after oral administration. However, because of the potential for adverse effects in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to clotrimazole or any component of the formulation
| Precautions | Renal impairment: Use with caution in patients with renal impairment; dose adjustment recommended., Dehydration: Ensure adequate hydration to prevent crystalluria., Neurologic effects: Use with caution in patients with neurological conditions; may cause agitation, seizures, or encephalopathy., Immunocompromised patients: Safety and efficacy not established for HIV patients with CD4 count < 100 cells/mm³. |
| Food/Dietary | No known food interactions. However, patients should avoid eating or drinking until the buccal tablet has fully dissolved, as food and liquid may disrupt adhesion and reduce efficacy. |
Loading safety data…
| Lactation Rating | L3 (Moderately Safe) - limited data; caution advised |
| Teratogenic Risk | Pregnancy Category X: Contraindicated due to risk of fatal fetal toxicity from ribavirin component (teratogenic in all animal species) and peginterferon alfa-2a (associated with increased fetal loss in primates). Avoid pregnancy during therapy and for 6 months after completion in female patients and female partners of male patients. |
| Fetal Monitoring | Negative pregnancy test required immediately before initiation, monthly during therapy, and 6 months post-therapy. Monitor for fetal exposure via ultrasound if pregnancy occurs. |
| Fertility Effects | Reversible oligospermia reported with ribavirin; may impair male fertility during treatment. No specific data on female fertility. Contraceptive counseling mandatory for both sexes during and 6 months after treatment. |
| Clinical Pearls | Sitavig (acyclovir buccal tablet) is indicated for recurrent herpes labialis. It is applied as a single dose to the upper gum region and left in place until dissolved. No need for additional oral antiviral cover. Avoid chewing or swallowing the tablet. Do not apply to oral mucosal lesions or inside the cheek. Do not apply to broken skin. |
| Patient Advice | Apply the tablet to the upper gum area as soon as symptoms (tingling, redness, blister) appear. · Do not chew, swallow, or crush the tablet. Allow it to dissolve naturally. · Avoid eating or drinking until the tablet has completely dissolved. · Do not touch or manipulate the tablet after placement. · Wash hands after application. · Do not use if you have a weakened immune system or are allergic to acyclovir. · This medication is for herpes labialis only, not for cold sores inside the mouth. |